Olink Explore 384 Inflammation Ⅱ Panel

The Olink Explore 384 Inflammation II Panel employs PEA technology to simultaneously analyze 384 inflammatory biomarkers from only 1 µL of plasma or serum. This high-sensitivity proteomics solution profiles essential pathways including immune signaling (cytokines, chemokines), inflammatory responses (acute-phase proteins, complement activation), host defense mechanisms (IL-17, TNF pathways), and tissue repair processes (matrix metalloproteinases, growth regulators), providing comprehensive insights for immunological research.

As a proteomics innovator, we present the Olink Explore 384 Inflammation II Panel—an advanced research solution for investigating immune-related pathologies. Expert-curated biomarkers spanning autoimmune, infectious, and fibrotic conditions undergo rigorous validation (specificity, precision, sensitivity, dynamic range), enabling robust quantification of low-abundance targets (1 µL plasma/serum input) with minimal matrix interference.

Submit Your Request Now

Olink Explore 384 infographic showing multiplex detection of 384 proteins across immune, metabolic, neurological, and cancer pathways

Panel Features
Panels List
Workflow
Why CP
Demo
Sample Requirements
Case
FAQ

What is the Olink Explore 384 Inflammation Ⅱ Panel

Customized panel for human

The Olink Explore 384 Inflammation II Panel leverages PEA technology to analyze 369 inflammatory biomarkers from 1 μL plasma/serum samples (processing 88 samples per run), delivering high sensitivity (<1 pg/mL) and reproducibility (<5% CV) through NPX normalization. The platform's modular architecture combines eight specialized subpanels for either broad immune profiling or focused pathway studies, supported by NIST-traceable quality controls to ensure reliable biomarker discovery.

Features of the pane

Species: Validated for human proteome studies only.
Proteins: 384 inflammation biomarkers analyzed simultaneously.
Sample: 1 µL plasma/serum input.
Readout: NPX-normalized quantitative values.
Platform: Olink Signature Q100 platform exclusive.

List of 384 human derived biomarkers

Protein category

The Olink Explore 384 Inflammation II Panel profiles 369 proteins across six functional categories: chemokines, cell adhesion molecules, growth factor binding proteins, enzymes, receptors, and other functional proteins (see Table. List of Olink Explore 384 Inflammation Ⅱ Panel). These biomarkers were selected through rigorous evaluation of their dynamic range and inflammatory pathway relevance, with functional characterization via UniProt, Human Protein Atlas, Gene Ontology, and DisGeNET databases confirming their roles in immune regulation, cellular interactions, metabolic processes, and complement activation.

Protein Functions

Biological process

Primarily linked to immune regulation, cytokine networks, and receptor interactions.

Disease area

Associated with RA, asthma, and infection-related pathways

The Application of Olink Explore 384 Inflammation ⅡPanel.

The Olink Explore 384 InflammationⅡpanel enables comprehensive profiling of 384 inflammatory proteins to investigate immune pathway dysregulation, providing researchers with a powerful tool for:

Comprehensive Immune Profiling

The panel enables parallel measurement of 384 inflammatory biomarkers, allowing researchers to systematically characterize immune dysregulation patterns in autoimmune disease models (e.g., rheumatoid arthritis, IBD) and infection studies;

Mechanistic Pathway Investigation

Researchers can utilize the panel to dissect cytokine networks, complement activation pathways, and acute-phase responses in cellular and animal models of inflammation;

Biomarker Discovery & Validation

The platform facilitates identification of novel protein signatures for experimental model stratification and therapeutic target validation in preclinical studies.

Workflow of Olink Proteomics

Why CPR

Disease-Optimized Research Tools

Preloaded with 68 validated biomarker ratios for autoimmune (RA, IBD) and infectious disease (sepsis) research models.

Multi-Omics Readiness

Seamless integration with transcriptomic/metabolomic data through standardized bioinformatics pipelines.

Technical Reproducibility

Achieves 98% inter-assay consistency across all targets using automated, standardized protocols.

Researcher Empowerment

Includes training modules for inflammation-specific data analysis and visualization techniques.

Demo Results of Olink Data

Volcano plot of candidate plasma proteins differentially expressed in JIA patients vs controls. Effect of 11 candidate plasma proteins associated with Juvenile idiopathic arthritis (JIA). (Cai, Y. X., et al. 2024)

Sample Requirements

Sample Type	Recommended Sample Size	Sample Quality	Pre-treatment and Storage	Sample Transport
Plasma/Serum/Body Fluid	40µL/sample	Protein concentration: 0.5mg/ml ~ 1mg/ml	Transfer to sterile containers, aliquot into 1.5 mL tubes or 96-well plates, and cryopreserve at -80°C.	Aluminum foil-sealed specimens require dry ice transport (-80°C)
Tissue
Cells
Exosomes
Other

Case Study

Genetic and Plasma Proteomic Approaches to Identify Therapeutic Targets for Graves' Disease and Graves' Ophthalmopathy

Journal: Immuno Targets and therapy
Year: 2025

The blood proteome is a major source of biomarkers and therapeutic targets. Through phylogenetic analysis, the pathogenic proteins and potential targets of Graves' disease (GD) and Graves' ophthalmopathy (GO) were searched.

The study used genome-wide association analysis (GWAS) for large-scale proteomic studies using the antibody-based Olink platform. The UK Biobank Pharma Proteomics Project is a pre-competitive consortium of 13 biopharmaceutical companies that funded the generation of multiplex, population-scale proteomics data using the Olink platform for proteomic analysis of plasma samples from 54,219 participants, collecting data on 2,923 proteins.

After Bonferroni correction, 62 proteins were identified as significantly associated with GD (Figure 1). In sensitivity analyses for proteins with more than two PQTLs, causality was not confounded by heterogeneity and pleiotropy. Eighteen of the 62 disease-causing proteins had consistent significance in GD GWAS replication analysis in the UKB database.

Volcano plot showing causal relationships between plasma proteins and Graves' disease (GD) pathogenesis Figure 1. Effects of plasma proteins on Graves' disease. (Ke, C, et al. 2025)

FAQs

What antibodies are used in the Olink detection panel?

Olink assays use antigen affinity-purified polyclonal or monoclonal antibodies, or a combination of both.

What is the sample size of Olink Explore and what is the standard sample size requirement for shipment?

The sample consumption of Olink Explore HT is ~2 μL. The sample volume used for Olink Explore 384 is per μL and the total sample volume used for Olink Explore 3072 is 6 μL. Sample preparation instruments require additional sample volume (dead volume). For our service charges, we require you to ship at least 40 μL of Olink Explore HT and Olink Explore 384 samples, and 80 μL of Olink Explore 3072 samples. This is to minimize possible evaporation effects during transportation, etc. Please note that we can return the remaining samples to you upon your request.

What is the hands-on time of the Olink Explore 3072/384?

For Olink Explore 3072/384, results were obtained within 36 hours; Operating time: <5 hours

References

Cai, Y. X., Chen, X. L., Zheng, D. S., et al. (2024). Integrated analysis of multi-omics data for the discovery of biomarkers and therapeutic targets for juvenile idiopathic arthritis. Journal of translational autoimmunity, 9, 100256. https://doi.org/10.1016/j.jtauto.2024.100256
Ke, C., Yu, Y., Li, J., et al. (2025). Genetic and Plasma Proteomic Approaches to Identify Therapeutic Targets for Graves' Disease and Graves' Ophthalmopathy. ImmunoTargets and therapy, 14, 87–98. https://doi.org/10.2147/ITT.S494692

* For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.

Online Inquiry